Prelude Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-208,861
| Closed | -$10.8M | – | 1919 |
|
|
2022
Q3 | $10.8M | Buy |
208,861
+191,661
| +1,114% | +$7.92M | 0.39% | 27 |
|
|
2022
Q2 | $426K | Buy |
+17,200
| New | +$379K | 0.01% | 887 |
|
|
2022
Q1 | – | Sell |
-18,500
| Closed | -$674K | – | 2469 |
|
|
2021
Q4 | $674K | Buy |
+18,500
| New | +$649K | 0.02% | 837 |
|
|
2019
Q3 | – | Sell |
-571
| Closed | -$5K | – | 2193 |
|
|
2019
Q2 | $5K | Buy |
+571
| New | +$6.61K | ﹤0.01% | 1530 |
|
|
2019
Q1 | – | Sell |
-1,076
| Closed | -$12K | – | 2318 |
|
|
2018
Q4 | $12K | Hold |
1,076
| – | – | ﹤0.01% | 1349 |
|
|
2018
Q3 | $14K | Buy |
+1,076
| New | +$13K | ﹤0.01% | 1394 |
|
|
2018
Q2 | – | Sell |
-983
| Closed | -$13K | – | 2035 |
|
|
2018
Q1 | $13K | Buy |
+983
| New | +$10.1K | ﹤0.01% | 1319 |
|
|
2017
Q4 | – | Sell |
-500
| Closed | -$4K | – | 1822 |
|
|
2017
Q3 | $4K | Sell |
500
-1,100
| -69% | -$9.14K | ﹤0.01% | 1529 |
|
|
2017
Q2 | $15K | Buy |
1,600
+1,400
| +700% | +$10.3K | ﹤0.01% | 1326 |
|
|
2017
Q1 | $1K | Sell |
200
-500
| -71% | -$3.6K | ﹤0.01% | 1466 |
|
|
2016
Q4 | $5K | Buy |
700
+171
| +32% | +$1.23K | ﹤0.01% | 1441 |
|
|
2016
Q3 | $3K | Buy |
+529
| New | +$2.5K | ﹤0.01% | 1521 |
|
|
2013
Q4 | – | Sell |
-1,820
| Closed | -$10K | – | 1993 |
|
|
2013
Q3 | $10K | Buy |
+1,820
| New | +$19.7K | ﹤0.01% | 1298 |
|
Other funds holding CCXI
Prelude Capital Management's CCXI Position: Q4 2022 in Review
Prelude Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 208,861 shares — an estimated $10.8M sold.
Prelude Capital Management first reported a position in CCXI in Q3 2013 and held it in 13 quarters. The position peaked at $10.8M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Prelude Capital Management reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Prelude Capital Management sold 208,861 ChemoCentryx, Inc. shares in Q4 2022, an estimated $10.8M.
- Prelude Capital Management first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 13 quarters.
- Prelude Capital Management's ChemoCentryx, Inc. position peaked at $10.8M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.